Togo vs United Arab Emirates: Access to anti-retroviral drugs, female
Togo
96.0%
in 2024
United Arab Emirates
97.0%
in 2024
Togo rank
14th
United Arab Emirates rank
12th
Access to anti-retroviral drugs, female over time
- Togo
- United Arab Emirates
How they compare
United Arab Emirates currently reports 97.0% against 96.0% in Togo, a difference of 1.0%.
The two have swapped places 4 times across 25 shared years of data; in 2000 it was United Arab Emirates ahead.
Togo ranks 14th and United Arab Emirates ranks 12th of 141 countries.
Across the 3 decades both report, Togo averaged higher in 2 and United Arab Emirates in 1.
Head to head by decade
| Decade | Togo | United Arab Emirates | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 4.6% | 21.0% | 16.4% | United Arab Emirates |
| 2010s | 51.6% | 31.5% | 20.1% | Togo |
| 2020s | 91.2% | 85.4% | 5.8% | Togo |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Togo or United Arab Emirates?
- United Arab Emirates, at 97.0% against 96.0% in Togo as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Togo and United Arab Emirates?
- 1.0%, with United Arab Emirates ahead.
- How many years of comparable data are there for Togo and United Arab Emirates?
- 25 years are reported by both, from 2000 to 2024.
- How do Togo and United Arab Emirates rank globally for access to anti-retroviral drugs, female?
- Togo ranks 14th and United Arab Emirates ranks 12th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.